NASDAQ$ACET
Adicet Bio Inc · Q1 2025 earnings
Q1 2025 earnings · · After market close · Investor relations
Briefing
Adicet Bio reported its first quarter 2025 financial results, highlighting progress in clinical trials for autoimmune diseases and cancer, and provided business updates.
Adicet Bio reported a net loss of $28.2 million for Q1 2025, a slight increase from $28.0 million in Q1 2024. The company's cash and cash equivalents stood at $150.4 million, and it expects this to fund operations into the second half of 2026. Key operational highlights include ongoing patient enrollment in Phase 1 trials for ADI-001 in autoimmune diseases and ADI-270 in ccRCC, with preliminary data expected in 2H/2025.
- Net loss for Q1 2025 was $28.2 million, compared to $28.0 million in Q1 2024.
- Cash and cash equivalents were $150.4 million as of March 31, 2025, down from $176.3 million at the end of 2024.
- Preliminary clinical data for ADI-001 in autoimmune diseases and ADI-270 in ccRCC are expected in the second half of 2025.
- ADI-001 received two new Fast Track Designations from the FDA for refractory SLE with extrarenal involvement and for SSc.
Headline financials
Revenue & EPS history
Adicet Bio · Revenue · Quarterly
$0
Forward guidance
Adicet Bio anticipates significant data milestones in the second half of 2025, with preliminary Phase 1 data expected from its ADI-001 and ADI-270 programs. The company expects its current cash, cash equivalents, and short-term investments to fund operating expenses into the second half of 2026.
Tailwinds
- Preliminary Phase 1 data for ADI-001 in autoimmune diseases and ADI-270 in ccRCC expected in 2H/2025.
- Enrollment expanded for ADI-001 Phase 1 trial to include lupus nephritis (LN) and systemic lupus erythematosus (SLE) patients.
- ADI-001 granted two new Fast Track Designations by the FDA for refractory SLE with extrarenal involvement and for SSc.
- Company expects to initiate enrollment for additional autoimmune diseases (SSc, IIM, SPS, AAV) in the ADI-001 Phase 1 trial in 3Q/2025.
- Cash position is expected to fund operating expenses into the second half of 2026.
Headwinds
- Clinical studies may fail to demonstrate adequate safety and efficacy of product candidates.
- Regulatory approval processes are lengthy, time-consuming, and inherently unpredictable.
- Positive results from preclinical or interim clinical studies may not necessarily be predictive of future study results.
- Ability to meet production and product release expectations may be challenging.
- Global economic conditions and public health emergencies could impact business and financial results.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 19 quarterly earnings reports · overlaid with Q1 2025
+1.1%
Avg return
Earnings day
+1.2%
Avg return
5 days after
-5.2%
Avg return
30 days after
52%
16 / 31 earnings
Positive
+29.7%
Q4 2021
Best reaction
-9.1%
Q2 2022
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +2.4% | -5.3% | — | |
| Q4 2025 | -3.2% | -1.6% | -4.0% | |
| Q3 2025 | -3.6% | -6.4% | -22.6% | |
| Q1 2025 | -6.9% | -7.5% | -7.9% | |
| Q4 2024 | -2.3% | +15.0% | -33.8% | |
| Q3 2024 | +1.5% | -3.8% | -19.8% | |
| Q2 2024 | +7.9% | +20.5% | +20.5% | |
| Q1 2024 | -2.8% | +11.1% | +0.7% | |
| Q4 2023 | +9.7% | +12.3% | +3.8% | |
| Q3 2023 | -4.9% | -10.3% | +4.9% | |
| Q2 2023 | +6.8% | -2.7% | -23.2% | |
| Q1 2023 | +4.1% | -4.5% | -14.9% | |
| Q4 2022 | -3.1% | -19.5% | -29.5% | |
| Q3 2022 | +1.9% | +11.0% | +3.8% | |
| Q2 2022 | -9.1% | -11.0% | -4.9% | |
| Q1 2022 | +8.6% | +13.1% | +9.6% | |
| Q4 2021 | +29.7% | +31.0% | +37.6% | |
| Q3 2021 | +3.2% | +0.8% | +49.7% | |
| Q2 2021 | +8.1% | -5.9% | +6.4% | |
| Q1 2021 | +1.5% | +7.7% | -22.5% | |
| Q4 2020 | -0.7% | +6.2% | -11.2% | |
| Q3 2020 | +5.9% | +9.2% | +22.3% | |
| Q2 2020 | +0.4% | +4.4% | -17.3% | |
| Q1 2020 | +9.1% | +10.3% | +24.6% | |
| Q4 2019 | -8.5% | -17.1% | -6.0% | |
| Q3 2019 | -5.3% | +6.7% | -85.2% | |
| Q2 2019 | -3.5% | -3.7% | -22.2% | |
| Q1 2019 | -4.6% | -7.3% | +1.3% | |
| Q4 2018 | -8.3% | -10.8% | -23.3% | |
| Q3 2018 | -5.8% | -5.2% | -2.7% | |
| Q2 2018 | +5.1% | -0.9% | +9.3% | |
| Q1 2018 | — | — | — | |
| Q4 2017 | — | — | — | |
| Q3 2017 | — | — | — | |
| Q2 2017 | — | — | — | |
| Q1 2017 | — | — | — | |
| Q4 2016 | — | — | — | |
| Q3 2016 | — | — | — | |
| Q2 2016 | — | — | — | |
| Q1 2016 | — | — | — | |
| Q4 2015 | — | — | — | |
| Q3 2015 | — | — | — | |
| Q2 2015 | — | — | — | |
| Q3 2014 | — | — | — | |
| Q2 2014 | — | — | — | |
| Q1 2014 | — | — | — | |
| Q4 2013 | — | — | — | |
| Q3 2013 | — | — | — | |
| Q2 2013 | — | — | — | |
| Q1 2013 | — | — | — | |
| Q4 2012 | — | — | — | |
| Q3 2012 | — | — | — | |
| Q2 2012 | — | — | — | |
| Q1 2012 | — | — | — | |
| Q4 2011 | — | — | — | |
| Q3 2011 | — | — | — | |
| Q2 2011 | — | — | — | |
| Q1 2011 | — | — | — | |
| Q4 2010 | — | — | — | |
| Q3 2010 | — | — | — | |
| Q2 2010 | — | — | — | |
| Q1 2010 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro